Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection.

NCT04308278 is registered in ClinicalTrials.gov with Labo'Life as lead sponsor.

NCT NCT04308278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04308278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection.
Lead sponsor
Labo'Life
Phase
Phase 4
Overall status
Recruiting
Start date
January 22, 2021
Completion date
August 30, 2028
Enrollment
88 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

ebv infection